- Home
- GH vs AXSM Comparison
GH vs AXSM Comparison
Compare GH & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- AXSM
- Stock Information
- Founded
- GH 2011
- AXSM 2012
- Country
- GH United States
- AXSM United States
- Employees
- GH N/A
- AXSM N/A
- Industry
- GH Medical Specialities
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- GH Health Care
- AXSM Health Care
- Exchange
- GH Nasdaq
- AXSM Nasdaq
- Market Cap
- GH 5.5B
- AXSM 5.1B
- IPO Year
- GH 2018
- AXSM 2015
- Fundamental
- Price
- GH $41.72
- AXSM $107.76
- Analyst Decision
- GH Strong Buy
- AXSM Strong Buy
- Analyst Count
- GH 21
- AXSM 15
- Target Price
- GH $52.81
- AXSM $170.20
- AVG Volume (30 Days)
- GH 2.7M
- AXSM 655.3K
- Earning Date
- GH 04-30-2025
- AXSM 05-05-2025
- Dividend Yield
- GH N/A
- AXSM N/A
- EPS Growth
- GH N/A
- AXSM N/A
- EPS
- GH N/A
- AXSM N/A
- Revenue
- GH $773,996,000.00
- AXSM $432,157,000.00
- Revenue This Year
- GH $19.53
- AXSM $63.52
- Revenue Next Year
- GH $21.92
- AXSM $63.32
- P/E Ratio
- GH N/A
- AXSM N/A
- Revenue Growth
- GH 28.20
- AXSM 72.16
- 52 Week Low
- GH $18.01
- AXSM $64.11
- 52 Week High
- GH $52.92
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- GH 43.79
- AXSM 46.37
- Support Level
- GH $38.86
- AXSM $103.15
- Resistance Level
- GH $52.92
- AXSM $120.00
- Average True Range (ATR)
- GH 2.91
- AXSM 3.51
- MACD
- GH -0.74
- AXSM 0.66
- Stochastic Oscillator
- GH 20.34
- AXSM 29.45
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.